Skip to content
    Guidelines & Consensus

    Project Orbis linked to faster oncology drug reviews in Canada, analysis finds

    Zaslavsky et alClinical Pharmacology and Therapeutics

    Project Orbis, established by the US Food and Drug Administration (FDA) in 2019, facilitates concurrent submission and review of oncology products among international regulatory partners. To determine the regulatory impact of this framework in Canada, researchers evaluated publicly available data on marketing authorization applications (MAAs) approved by Health Canada between September 20, 2019, and the end of 2025. The analysis examined US-Canada submission gaps, approval gaps, overall time to regulatory decision, involved tumor types, and sponsor participation.
    During the study window, Health Canada authorized 97 Orbis and 161 non-Orbis oncology MAAs. Oncology drugs reviewed under the Project Orbis initiative achieved shorter median submission gaps between the US and Canada as well as shorter median approval gaps relative to standard non-Orbis oncology applications. Additionally, Orbis applications had a shorter median time to regulatory decision, which varied across accelerated and standard review pathways.
    Review timelines remained consistent with established Health Canada performance metrics. Notably, median time to decision for Orbis Type A reviews remained comparable across both standard and priority review MAAs. While these findings confirm Health Canada's active involvement and accelerated regulatory approvals under Project Orbis, additional evaluation is required to evaluate whether these timelines translate into faster patient access, taking into account downstream health technology assessments and provincial reimbursement negotiation processes.

    Key Takeaways

    • Between September 20, 2019, and the end of 2025, Health Canada approved 97 Project Orbis oncology marketing authorization applications alongside 161 non-Orbis oncology applications.
    • Project Orbis applications demonstrated shorter median US-Canada submission gaps, shorter median approval gaps, and shorter median times to regulatory decision compared with non-Orbis oncology submissions.
    • Median time to decision for Project Orbis Type A applications was similar between standard and priority review pathways, meeting Health Canada performance standards.
    Read the original sourceClinical Pharmacology and Therapeutics